Volume | 2,858 |
|
|||||
News | - | ||||||
Day High | 3.4999 | Low High |
|||||
Day Low | 3.30 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GT Biopharma Inc | GTBP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.37 | 3.30 | 3.4999 | 3.30 | 3.195 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
89 | 2,858 | $ 3.36 | $ 9,614 | - | 2.9539 - 16.11 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:51:46 | 1 | $ 3.41 | USD |
GT Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.56M | 1.38M | - | 0 | -7.6M | -5.50 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GT Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GTBP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.71 | 3.71 | 2.9539 | 3.17 | 8,232 | -0.41 | -11.05% |
1 Month | 4.59 | 4.68 | 2.9539 | 3.70 | 7,087 | -1.29 | -28.10% |
3 Months | 4.91 | 5.21 | 2.9539 | 4.28 | 13,304 | -1.61 | -32.79% |
6 Months | 8.40 | 9.90 | 2.9539 | 6.82 | 82,353 | -5.10 | -60.71% |
1 Year | 10.80 | 16.11 | 2.9539 | 8.60 | 225,491 | -7.50 | -69.44% |
3 Years | 399.00 | 591.993 | 2.9539 | 136.02 | 212,250 | -395.70 | -99.17% |
5 Years | 165.00 | 591.993 | 2.9539 | 154.32 | 243,732 | -161.70 | -98.00% |
GT Biopharma Description
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. |